Azoospermia Diagnosis: A Comprehensive Guide for Male Infertility Evaluation

Introduction

Male infertility significantly contributes to challenges faced by couples trying to conceive, affecting approximately 15% of the global population. Azoospermia, the most severe form of male infertility, is characterized by the complete absence of sperm in the ejaculate. This condition impacts around 1% of all men and a substantial 10% to 15% of men experiencing infertility. Azoospermia Diagnosis is critical for effective management and treatment strategies. It’s essential to differentiate azoospermia from aspermia, which refers to the total absence of ejaculate. Many testicular disorders, often untreatable, lead to azoospermia, highlighting the importance of accurate and timely diagnosis.

Azoospermia is broadly classified into pre-testicular, testicular, and post-testicular types, as detailed in Table 1. Etiologic Classification According to Pre-testicular, Testicular, and Post-testicular Causes. Furthermore, it’s categorized based on the presence or absence of duct obstruction: obstructive azoospermia (OA) and nonobstructive azoospermia (NOA), also known as primary testicular failure. Distinguishing between OA and NOA is paramount as it dictates the approach to treatment and management. Advancements in assisted reproductive technologies now offer various options for couples struggling with conception due to male infertility, even in cases of azoospermia.

Approximately 40% of azoospermic men are diagnosed with OA. Causes of OA include congenital bilateral absence of the vas deferens (CBAVD), ejaculatory and epididymal duct obstruction, seminal vesicle atresia, infections within the genitourinary tract leading to blockages, and surgical procedures like vasectomies causing complete obstruction. In OA, spermatogenesis is often unimpaired, making surgical correction of blockages and assisted reproductive techniques viable treatment paths.

However, NOA is more prevalent, accounting for about 60% of azoospermia cases, making it the most common type. NOA typically arises from severe spermatogenesis defects, frequently due to primary testicular failure or hypothalamic-pituitary dysfunction. The precise cause of NOA is often idiopathic. Despite the complexities, advanced assisted reproductive techniques offer hope for men with NOA, including primary testicular failure.

Testicular biopsies from men with severe spermatogenic failure often reveal areas of normal sperm production. Sperm from these areas can be retrieved using testicular sperm extraction (TESE) or testicular sperm aspiration (TESA) and utilized in advanced techniques like intracytoplasmic sperm injection (ICSI). Sperm obtained directly from the testes and used in IVF with ICSI generally leads to healthy offspring.

Healthcare professionals encounter significant challenges in managing infertile men with spermatic failure. Diagnostic tools for azoospermia include hormonal assessments, semen biomarkers, ultrasonography, testicular biopsy, and vasography. Transrectal ultrasound is particularly valuable for diagnosing distal obstructions in the male reproductive system.

Etiology

In obstructive azoospermia (OA), spermatogenesis is generally functional. Conversely, the etiology of nonobstructive azoospermia (NOA) is frequently idiopathic.

Nonobstructive azoospermia (NOA) can stem from a variety of factors, including:

• Anabolic steroid use
• Androgen insensitivity
• Chemotherapy treatments
• Congenital absence of germ cells, known as Sertoli cell-only syndrome
• Exposure to heavy metals
• Hyperprolactinemia
• Hypogonadotropic hypogonadism, such as in Kallmann syndrome
• Impaired sperm production due to chromosomal abnormalities like Klinefelter syndrome or Y chromosome microdeletions in AZFa, AZFb, or AZFc subregions
• Infections, including mumps and orchitis
• Radiation therapy
• Spermatogenic arrest (maturation arrest)
• Testicular torsion
• Testosterone supplementation therapy
• Translocation or inversion of azoospermia factor cryptorchidism
• Varicoceles

Table

Table 1. Etiological Classification According to Pre-Testicular, Testicular, and Post-Testicular Causes.

Epidemiology

Infertility affects approximately 15% of couples globally. Male azoospermia is present in about 1% of the male population and 10% to 15% of infertile men. Estimates suggest that at any given time, around 600,000 men of reproductive age in the United States are azoospermic, with the majority having nonobstructive azoospermia (NOA).

Men with azoospermia also face an elevated risk of cancer compared to the general population. Between 5% and 8% of men diagnosed with testicular cancer are azoospermic. The precise incidence of azoospermia remains unclear because infertility is not a reportable condition, is often managed in private physician offices, and is likely underreported in developing countries where advanced treatments are either financially inaccessible or unavailable.

Pathophysiology

Azoospermia classifications include testicular/post-testicular and obstructive/nonobstructive types. The classification based on obstruction is often considered more clinically useful and practical. See Table 2. Types of Azoospermia and Causes for detailed categorization.

The exact pathophysiology of azoospermia is not always clear; however, in some instances, it is linked to abnormal ciliary function and poor mucus quality.

Pre-testicular azoospermia is generally caused by endocrine abnormalities related to the hypothalamus, pituitary gland, and testes. Testicular azoospermia typically involves disorders affecting spermatogenesis directly. Post-testicular azoospermia results from ductal obstructions anywhere along the male reproductive tract.

Pre-Testicular Causes of Azoospermia

Pre-testicular causes, also known as secondary testicular failure, usually arise from underlying endocrine disorders. Although less common, endocrinopathies are found in up to 3% of subfertile men.

Pre-testicular azoospermia can be either congenital or acquired and may be associated with conditions such as:

Post-Testicular Causes of Azoospermia

Table

Table 2. Types of Azoospermia and Causes.

History and Physical Examination

A thorough evaluation is crucial for patients presenting with azoospermia. This evaluation should include a detailed medical, sexual, and surgical history. Specific attention should be paid to histories of genital trauma, drug allergies, medications (especially gonadotropins, anabolic steroids, testosterone supplementation, and toxins), chemotherapy, and exposure to pesticides or radiation. A history of genitourinary infections and sexually transmitted diseases is also essential.

Physical examination is a vital component in the assessment of azoospermia. The examination should be conducted with the patient in both supine and standing positions. The room temperature should ideally be maintained between 36°C to 37°C (96.8°F to 100.4°F).

Assess for the presence of a varicocele. Varicocele grading is relevant to disease progression and treatment planning. Evaluate the development of secondary sexual characteristics. Decreased body, axillary, and pubertal hair distribution can indicate low androgen levels. Palpate the thyroid gland and auscultate the heart and lungs. Breast and abdominal examinations should also be performed.

Examination of the male genitalia is particularly important. Palpate the testes, noting their length, width, and volume. Reduced testicular size is often associated with impaired spermatogenesis. Normal testicular size is generally 20 cc or greater, with a typical length of 4 cm, though measurements can vary slightly by ethnicity. Patients with obstructive azoospermia (OA) often have a normal hormonal profile and unremarkable testicular size, although some with late maturational arrest may present similarly. Bilateral atrophic or hypotrophic testes combined with elevated FSH levels typically indicate primary testicular failure, which is associated with poorer fertility outcomes, although ICSI may still be an option.

Palpate the vas deferens and epididymis bilaterally, noting their consistency. Carefully document the absence of one or both vas deferens, which is often linked to cystic fibrosis gene mutations. A digital rectal examination is essential to rule out masses and assess the size and consistency of the prostate gland. Prominent seminal vesicles may be palpable in cases of ejaculatory duct obstruction.

Evaluation

Semen Analysis

Azoospermia diagnosis necessitates at least two separate semen analyses, each preceded by 3 days of sexual abstinence. In azoospermic patients with normal ejaculate volume, the underlying issue is likely spermatogenic failure or obstruction located between the testes and seminal vesicles. Patients with azoospermia, low semen volume, and normal-sized testicles may have ejaculatory duct obstruction or ejaculatory dysfunction. Therefore, in cases of absent ejaculate (aspermia) or low ejaculate volume (<1.5 mL), post-ejaculatory urine analysis is recommended to rule out retrograde ejaculation.

Hormonal Evaluation

In the azoospermia evaluation, especially when physical examination reveals normal testicle size and consistency, a comprehensive endocrinological assessment is crucial for accurate diagnosis and treatment planning. Obtain hormonal profiles, including total and free testosterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, and estradiol levels, along with a thyroid profile. In obstructive azoospermia (OA), FSH levels are typically decreased or within the normal range. Conversely, nonobstructive azoospermia (NOA) often presents with elevated FSH levels, particularly if testes are smaller than normal. However, there can be overlap, and FSH levels alone may not definitively differentiate between OA and NOA. Generally, higher FSH levels suggest a greater likelihood of significant spermatogenic failure. While testicular biopsy might be needed for definitive diagnosis in some cases, it is often not necessary for initial diagnosis.

Hypogonadotropic hypogonadism is a less common cause of NOA, accounting for no more than 2% of infertile males. Potential causes include Kallmann syndrome, androgen-induced hypogonadism (from testosterone supplementation), brain tumors, trauma, and radiation. The incidence of azoospermia related to testosterone supplementation is increasing due to rising anabolic steroid abuse, and many patients and even some physicians are unaware of the negative impact of testosterone therapy on sperm counts and spermatogenesis.

Imaging (Scrotal Ultrasonography)

Scrotal ultrasound is increasingly important in male infertility evaluation and is becoming a routine diagnostic tool. It allows for precise measurement of testicular size and can detect cysts, varicoceles, spermatoceles, and lesions not easily found by other methods. It can also aid in differentiating between obstructive and nonobstructive azoospermia. Ultrasound findings suggestive of obstructive azoospermia (OA) include ectasia of epididymal tubules and/or rete testis, abnormal epididymal echogenicity, or dilated proximal vas deferens. Testicular volume, epididymal head size, and the resistive index of intratesticular vessels tend to be higher in OA patients compared to those with nonobstructive azoospermia (NOA). Transrectal ultrasonography can evaluate seminal vesicles and detect ejaculatory duct cysts. Absence of seminal vesicles may indicate a cystic fibrosis gene mutation (CFTR). If seminal vesicles are absent or dilated/enlarged, an obstructive etiology is likely.

Ultrasound examinations are painless and cost-effective. Communication with the radiologist about key factors to assess during a scrotal ultrasound for male infertility is beneficial. Routine comprehensive sonographic evaluation is recommended to aid in azoospermia diagnosis and differentiation between obstructive and nonobstructive causes.

Genetic Testing

Klinefelter Syndrome

Cytogenetic abnormalities are found in approximately 5% of men with nonobstructive azoospermia (NOA). Klinefelter syndrome, characterized by an extra X chromosome (XXY), is the most common sex chromosomal abnormality. Phenotypically male, these patients exhibit variable clinical presentations, and about 50% remain undiagnosed until infertility evaluation. The overall incidence is approximately 1 in 500 to 800 men, accounting for 3% of infertile men. Histological examination typically shows Sertoli cell-only syndrome in Klinefelter patients. Characteristics of Klinefelter syndrome include:

• Above-average height
• Longer legs, shorter torso, and wider hips compared to peers
• Poor muscle tone
• Impaired fine motor skills, dexterity, and coordination
• Absent, delayed, or incomplete puberty
• Reduced muscle mass and less facial and body hair post-puberty compared to peers
• Small, firm testicles
• Small penis
• Enlarged breast tissue (gynecomastia)
• Infertility

Germ cell and sperm presence varies significantly in these individuals. Microscopic testicular sperm extraction (micro-TESE) can retrieve viable sperm in about 50% of men with Klinefelter syndrome. Data is conflicting on using age or testosterone levels to predict successful sperm retrieval in this population. Sperm retrieval procedures should be limited to adults and are not recommended for boys and adolescents with Klinefelter syndrome.

Adult men with Klinefelter syndrome also have higher rates of hypogonadism, diabetes, thromboses, metabolic syndrome, various cancers (breast, hematological, and extragonadal germ cell tumors), and cardiovascular disease. Appropriate counseling and referrals are essential.

Other Genetic Disorders

The overall incidence of chromosomal abnormalities in infertile men is around 6%, with the highest risk in men with nonobstructive azoospermia (NOA). Absence of one or both vas deferens and/or seminal vesicles on transrectal ultrasound strongly suggests a genetic association with cystic fibrosis, present in about 80% of cases. Testing both the patient and partner for the cystic fibrosis gene (CFTR) is recommended. Other abnormalities include Robertsonian and reciprocal translocations and chromosomal inversions.

Karyotype and Y chromosome microdeletion testing should be offered to all men with primary testicular failure. About 6% of NOA men have Y chromosome microdeletions involving AZFa and/or AZFb subregions. These men typically have very low sperm retrieval rates and should be counseled about donor sperm for ICSI or adoption.

Microdeletions of the AZFc subregion occur in about 4% of NOA cases, presenting a less severe infertility issue but can be inherited by male offspring. Up to 30% of NOA men have Y chromosome microdeletions. Complete deletions of AZFa, AZFb, or AZFc generally result in NOA. Histologically, about 46% of men with AZFc microdeletions show Sertoli cell-only syndrome, and 38% have maturational arrest. Rare atypical Y chromosome microdeletions also occur, requiring individualized counseling and treatment.

Genetic testing should also be considered for men with hypogonadotropic hypogonadism, as about one-third have a genetic lesion with variable inheritance patterns. For instance, 13 genes have been identified contributing to maturational arrest leading to NOA.

Differentiating Obstructive from Nonobstructive Azoospermia

Obstructive azoospermia (OA) patients typically have normal FSH and LH levels and normal-sized testes. Testicular ultrasound may show an increased intratesticular resistive index or dilated ducts in the testes, epididymis, or proximal vas.

Nonobstructive azoospermia (NOA) patients may have normal or elevated FSH and LH levels. Testes size can be normal, hypotrophic, or atrophic. If differentiation remains unclear, a testis biopsy may be necessary.

Further Evaluation of Low Semen Volume Azoospermia

Azoospermia patients with semen volumes consistently below 1.5 ml are likely to have retrograde ejaculation, ejaculatory duct cysts, or congenital absence of the vas deferens or seminal vesicles. Post-ejaculation urine analysis can identify retrograde ejaculation. Physical examination can detect absent vas deferens. Transrectal ultrasonography or cystoscopy can identify ejaculatory duct cysts. Seminal vesicles can be evaluated via transrectal ultrasonography.

Further Evaluation for Obstructive Azoospermia

In obstructive azoospermia (OA), hormonal profiles and testicular volume are typically normal.

Epididymal dilation, hydrocele presence, or vas deferens absence suggest obstruction. Azoospermia due to vasal or epididymal obstruction often has a normal seminal fluid biochemical profile. Testicular biopsy is indicated in azoospermic men with normal testicular exams and hormonal profiles. Karyotype evaluation is not required, but CFTR gene mutation assessment is recommended to rule out cystic fibrosis.

Further Evaluation of Nonobstructive Azoospermia

Azoospermia diagnosis is confirmed with at least two separate semen samples. In nonobstructive azoospermia (NOA), abnormal hormonal profiles, particularly elevated FSH levels, suggest significant spermatogenic issues. With normal hormonal profiles, testicular biopsy can further assess spermatogenesis, definitively diagnosing conditions like maturational arrest and Sertoli cell-only syndrome. Karyotype analysis, genetic testing, and Y chromosome microdeletion tests should be performed to assess genetic abnormalities. Endocrinological abnormalities are diagnosed and managed accordingly.

Diagnostic Testicular Biopsy

Testicular tissue is heterogenous, and spermatogenesis occurs in foci, making biopsy less frequently used for diagnosis. Testicular characteristics and lab findings are good but imperfect indicators of NOA. Testicular sperm extraction (TESE) can be performed at specialized centers, allowing sperm cryopreservation and avoiding diagnostic biopsy. Normal testicular biopsy suggests obstruction, requiring vasography to pinpoint the blockage and subsequent surgical repair or sperm retrieval. Serum testosterone levels can be low, normal, or high depending on the defect severity. Only one testis biopsy is needed for histological diagnosis, with the larger testis usually selected.

Testicular Etiologies

Direct testicular pathology can result from varicocele-induced damage, undescended testes, testicular torsion, mumps orchitis, medication toxicity, radiation, hereditary abnormalities, and idiopathic causes. Essential testicular failure with azoospermia, or NOA, is best managed by testicular sperm collection, if possible, for ICSI. Higher serum FSH levels and smaller testicular volumes indicate more severe spermatogenic disruption and poorer outcomes in NOA.

Generally, maturational arrest, Sertoli cell-only syndrome, and Y chromosome microdeletions (AZFa, AZFb, or AZFc) are permanent and untreatable forms of NOA. However, micro-TESE may achieve sperm retrieval in approximately 50% of cases.

Other causes of azoospermia include XYY syndrome, myotonic dystrophy, Noonan syndrome, 5-alpha-reductase deficiency, androgen insensitivity syndrome, and vanishing testis syndrome. Varicoceles have a confirmed negative impact on semen and testes, and varicocelectomy has been shown to improve sperm parameters and testicular function. However, only a small percentage of azoospermia cases due to testicular failure benefit from varicocele surgery.

Undescended Testes

Undescended testes (cryptorchidism) are the most common genital condition in boys and young males, noted in 2.7% of newborns and up to 0.8% of 1-year-olds. Distinguish cryptorchid testes from retractile testes, where overactive cremasteric muscles cause intermittent inguinal canal or high scrotum positioning. Most men with a history of unilateral undescended testes can father children. Testicular volume and age at orchiopexy are independent predictors of fertility and sperm retrieval potential in men with cryptorchidism history.

Testicular Torsion

Testicular torsion occurs in about 1 in 4,000 males under 25. It requires prompt surgical exploration with detorsion and bilateral orchidopexy due to the risks of nonoperative management. Testicular preservation is typically possible if surgery is within 6 hours. Non-absorbable sutures are usually used for orchidopexy (at least 3 fixation points per side), and prophylactic orchidopexy on the contralateral testis is customary during surgery.

Treatment / Management

Azoospermia Management

In the era of advanced assisted reproductive techniques, infertile couples have multiple options to achieve biological parenthood.

Obstructive Azoospermia

The primary goal in managing obstructive azoospermia (OA) is to correct the obstruction surgically using reconstructive techniques like vasoepididymostomy and vasovasostomy. Assisted reproductive techniques are crucial for patients with congenital absence of vas deferens, as surgical reconstruction is not feasible. For ejaculatory duct obstruction, transurethral resection is performed to restore duct patency. Intraoperative vasography improves outcomes for vasoepididymostomy. Transurethral resection improves semen parameters in 50% to 70% of cases.

Sperm retrieval for assisted reproduction is an excellent option for OA management, with successful sperm recovery rates near 100%. ICSI enhances pregnancy rates due to motile sperm and cryopreservation capabilities. For OA patients where surgical repair is not possible or female factors significantly contribute to infertility, sperm retrieval for assisted reproduction is highly effective. Surgical bypass or repair is feasible in less than 50% of OA cases.

Epididymal obstruction is the most common site. Current vasoepididymostomy success rates are 85% patency and 50% spontaneous pregnancy. Sperm collection and cryopreservation during surgery are recommended if the initial outcome is unsuccessful. Inguinal approaches for microsurgical vasovasostomy and laparoscopic/robotic techniques for vas isolation before microsurgical anastomosis have been described.

For OA, microsurgical epididymal sperm aspiration (MESA) is optimally used for sperm retrieval when possible, almost always successful for extra-testicular obstructions. Intratesticular blockages require TESE or TESA. Post-vasectomy obstructions are treated with microscopic vasectomy reversals, achieving 90% to 97% postoperative patency rates. Robotic surgeries offer similar success rates.

Obstructions from scarring, inflammation, or ejaculatory duct cysts are typically treated with transurethral resection of the duct. Reported pregnancy rates post-procedure range from 12.5% to 31%, with potential side effects including failure, incontinence, reflux into seminal vesicles and ejaculatory ducts, and epididymitis. Intraoperative transrectal ultrasound and methylene blue use to verify patency can reduce complications and improve safety. Transurethral laser incision of the ejaculatory duct with seminal vesiculoscopy is also used, but its advantages over standard procedures are unclear.

Percutaneous procedures like TESE, percutaneous epididymal sperm aspiration, and percutaneous testicular biopsy can obtain sperm for couples desiring fertility. However, microdissection testicular sperm extraction (micro-TESE) techniques report the highest sperm retrieval success rates.

Nonobstructive Azoospermia

Advanced assisted reproductive techniques are necessary for most nonobstructive azoospermia (NOA) patients. Both ICSI and micro-TESE are beneficial. Testicular sperm aspiration (TESA) involves percutaneous needle insertion into testicular parenchyma. Sperm retrieval failure rates in NOA are high and vary with etiology. Overall sperm retrieval success is reported up to 75%, but averages around 50%, with significant vascular injury risk. Chromosomal abnormalities and DNA damage in sperm are relatively high in NOA patients, and inheritable infertility genes may be passed to male offspring. Repeat micro-TESE can be successful if needed.

Men with azoospermia from testosterone supplementation therapy have excellent spermatogenesis recovery chances by discontinuing treatment and waiting. Most recover 85% of pretreatment sperm counts within a year and nearly all within two years.

To stimulate spermatogenesis in hypogonadotropic hypogonadism or pre-testicular azoospermia, gonadotropin analogs or FSH and HCG are used. Preferred therapy includes HCG (3,000 IU to 10,000 IU injections 2-3 times weekly) plus anastrozole, clomiphene, FSH, or tamoxifen.

This therapy has shown success in achieving some sperm in the ejaculate of 75% to 77% of men with NOA due to hypogonadotropic hypogonadism, but treatment may take up to 6 months. Pulsatile GnRH is an option but is usually more expensive without substantial benefit over standard treatment. Testosterone therapy is specifically not recommended.

While up to 11% of azoospermic men on hormone therapy (usually clomiphene) show improvement with sperm in ejaculate, therapy standardization and high-quality randomized trials are lacking. Many experts and the European Association of Urology (EAU) do not generally recommend hormone therapy for NOA and primary hypogonadism. Micro-TESE and ICSI are the main treatments for these men. Overall pregnancy success with these techniques is no more than 25% and is costly.

The role of estrogen receptor modulators, gonadotropins, and aromatase inhibitors in men with primary hypogonadism and NOA is controversial. They are frequently used to improve sperm parameters in oligozoospermic men, with some supporting evidence. However, their effectiveness in improving sperm retrieval rates via TESE or TESA is uncertain and unproven. Optimal protocols and dosing are undetermined, though a progressive protocol starting with clomiphene and escalating to HCG has been proposed. Potential side effects exist, but hormone stimulation therapy remains common clinical practice due to the lack of other treatments.

Hypogonadotropic hypogonadism treatment is relatively effective. One regimen for azoospermic men due to hypogonadotropic hypogonadism involves pulsatile GnRH administration (5 mcg to 20 mcg every 2 hours) via portable infusion pump. Sperm return in semen is generally noted after 6 months, and 77% of initially azoospermic men showed spermatogenesis after 12 to 24 months of treatment.

FSH stimulation before GnRH therapy appears to improve outcomes. GnRH is effective only in men with normal pituitary activity. Gonadotropin treatment with HCG (with or without FSH) is preferred for decreased or absent pituitary function. Suggested HCG dosage is 1000 IU to 3000 IU 2-3 times weekly, typically leading to sperm production in 3 to 6 months. If unsuccessful, FSH is added at 75 IU to 150 IU twice weekly. Overall spermatogenesis success rate from medical therapy of hypogonadotropic hypogonadism is about 75%. If medical treatment fails, assisted reproductive techniques are recommended.

Men with NOA have a higher incidence of other health disorders, including pituitary prolactinomas, various neoplasms (Sertoli cell, Leydig cell, and germ-cell tumors), and a threefold higher risk of future malignancy compared to infertile men without azoospermia. About 30% of NOA men also have testosterone deficiency, usually from Leydig cell dysfunction.

Absolute contraindications for sperm retrieval attempts in NOA patients are Y chromosome microdeletions of AZFa or AZFb subregions and post bilateral orchiectomy, as sperm retrieval rates will be zero. Even in Sertoli cell-only syndrome, micro-TESE has a reported sperm retrieval success rate of at least 24%, with a mean average around 50%. No degree of testicular atrophy or FSH elevation can definitively predict sperm retrieval success or failure.

Good predictors of successful sperm retrieval with micro-TESE in NOA men include focal Sertoli cell-only syndrome, late-stage maturation arrest (compared to early maturation arrest), hypospermatogenesis (vs. maturation arrest or Sertoli cell-only syndrome), and viable sperm visible in seminiferous tubules on testis biopsy. Micro-TESE has about a 50% sperm retrieval success rate, and ICSI also has approximately 50% success, yielding an overall pregnancy rate of only 25%. Given costs and potential genetic implications, couples should seriously consider artificial insemination or ICSI using donor sperm or adoption before advanced reproduction treatments.

Differential Diagnosis

The differential diagnosis for azoospermia includes:

• Congenital unilateral absence of the vas deferens (CUAVD) or congenital bilateral absence of the vas deferens (CBAVD)
• Congenital adrenal hyperplasia
• Congenital varicocele
• Cryptorchidism
• Ejaculatory duct obstruction or cysts
• Epididymitis and prostatitis
• Erectile/sexual dysfunction
• Hyperprolactinemia
• Hypogonadotropic hypogonadism
• Kallmann syndrome
• Long-term testosterone supplementation
• Medication side effects (tamsulosin)
• Mumps orchitis
• Pituitary tumors
• Post bilateral orchiectomy
• Post bilateral vasectomy
• Post-TURP
• Retrograde ejaculation
• Spermatoceles
• Testosterone supplementation or replacement therapy

Prognosis

The prognosis for azoospermia depends heavily on the underlying cause. Obstructive azoospermia (OA), often due to surgically correctable conditions like congenital absence of the vas deferens or post-surgical blockages, typically has a favorable prognosis. Surgical interventions or assisted reproductive techniques are often effective in achieving conception for individuals with OA.

Nonobstructive azoospermia (NOA), primarily caused by testicular failure, presents a more challenging prognosis. While advanced technologies like testicular sperm extraction (TESE) and intracytoplasmic sperm injection (ICSI) can enable conception, success rates vary, and the condition may be untreatable in some cases if spermatogenesis is severely disrupted. Accurate diagnosis, tailored treatment plans, and ongoing support are crucial for influencing prognosis, emphasizing a comprehensive and individualized approach to azoospermia management.

Complications

Complications associated with azoospermia and its surgical treatments include:

1. Hematoma formation post-surgery
2. Infection
3. Parenchymal fibrosis of the testis
4. Testicular atrophy

Azoospermia can also cause significant emotional distress, impacting mental health and straining relationships. Fertility treatments, while hopeful, can impose financial and emotional burdens. The psychological impact of infertility and societal stigmas around male reproductive health further complicate the challenges of azoospermia.

Deterrence and Patient Education

Deterrence and patient education are vital in azoospermia management, focusing on prevention and effective handling of the condition. Deterrence involves raising awareness about lifestyle factors contributing to azoospermia, such as smoking, excessive alcohol, testosterone supplementation, and environmental toxin exposure. Educating patients about healthy lifestyles, balanced diets, and stress management promotes reproductive well-being.

Patient education is also crucial for understanding the causes and classifications of azoospermia, empowering informed decisions about reproductive health. Proper counseling, testing, and treatment can offer most male infertility patients, including those with azoospermia, the opportunity to father biological children. By increasing awareness and providing comprehensive information, healthcare professionals can help deter modifiable risk factors and equip patients to navigate azoospermia complexities, enhancing their proactive engagement in reproductive health management.

Pearls and Other Issues

Providing patients with realistic expectations of treatment success at the initial visit is important, as public perception of modern medicine’s capabilities in treating azoospermia and male infertility is often exaggerated.

Azoospermia diagnosis requires two separate semen samples showing no sperm. Despite azoospermia, most patients can be helped with sperm retrieval and ICSI.

Detailed history, physical examination, and initial hormonal screening (testosterone, FSH, LH, prolactin, estradiol) are necessary to classify azoospermia as obstructive or nonobstructive. Karyotype analysis and genetic testing for Y chromosome microdeletions should be offered to azoospermic men without an apparent cause. Genetic testing is recommended before sperm retrieval or testis biopsies.

Selective scrotal and transrectal ultrasound examinations can further aid in azoospermia diagnosis and classification.

Karyotype and genetic screening are advised before sperm retrieval to avoid unnecessary surgeries.

• Missing vas deferens or seminal vesicle suggests cystic fibrosis gene mutation. Test for CFTR.
• Bilateral small, firm testes suggest Klinefelter syndrome. Perform karyotype.
• Small or normal testicular size and elevated FSH suggest NOA from primary testicular disorder like maturational arrest, Sertoli cell-only syndrome, or Y chromosome microdeletions. Consider genetic testing and testis biopsy.
• Normal testicular size with low or normal FSH suggests OA. Micro-TESE, TESA, or MESA is reasonable for ICSI in most azoospermia cases EXCEPT primary testicular failure due to Y chromosome microdeletions of AZFa, AZFb, or AZFc, where donor sperm or adoption should be considered.
• Maturational arrest and Sertoli cell-only syndrome have substantially lower sperm retrieval success rates than other NOA causes.
• No FSH level elevation or testicular atrophy degree can guarantee no sperm will be found on retrieval.
• FSH stimulation to increase sperm count before biopsy and retrieval is controversial and not currently recommended.
• Testosterone supplementation has no role in male infertility or azoospermia treatment.
• Overall sperm retrieval success rate in NOA is about 50%.
• Overall successful pregnancy rate with ICSI is about 50%.

Obstructive azoospermia (OA) is effectively treated with surgical reconstruction or sperm retrieval and ICSI. Reconstruction is preferred in ideal situations, but sperm retrieval with ICSI is better for secondary male infertility factors, concomitant female factors, or expected poor surgical outcomes.

Infertility and azoospermia post-testosterone supplementation are a growing issue. All reproductive-age male patients should be informed about testosterone supplementation’s potential negative effects on sperm counts. This can be partially offset by adding clomiphene to testosterone replacement therapy.

Most men with azoospermia have the nonobstructive type, where sperm retrieval followed by ICSI is often the best option. Most of these men will still provide viable sperm for assisted reproduction, with few exceptions.

Enhancing Healthcare Team Outcomes

Azoospermia is a significant cause of male infertility among couples trying to conceive. Collaborative healthcare approaches are vital for patient-centered care and optimal outcomes. Physicians, advanced practitioners, nurses, pharmacists, and other professionals need comprehensive skills to address azoospermia’s multifaceted aspects. Classifying and diagnosing azoospermia involves detailed history, physical exams, hormonal investigations, ultrasonography, and genetic testing. Strategizing treatments, procedures, and protocols is key for infertile couples.

Evidence-based practices, continuous learning, and adapting to medical advancements are crucial. Physical and emotional support are also essential to enhance physicians’ ability to recommend treatments with appropriate counseling and patient expectations. Collaboration with radiologists, urologists, reproductive endocrinologists, OB/GYN specialists, and their nursing teams is imperative for the best outcomes. Trained nurses are integral to the interprofessional team.

Care coordination ensures seamless transitions across diagnostic, therapeutic, and follow-up phases, optimizing resource use, streamlining processes, and fostering continuous care addressing both medical and emotional azoospermia dimensions. Interprofessional teams can collectively enhance patient-centered care, improve outcomes, prioritize safety, and elevate overall team performance in azoospermia management.

Review Questions

Access free multiple choice questions on this topic.

References

1.Aziz N. The importance of semen analysis in the context of azoospermia. Clinics (Sao Paulo). 2013;68 Suppl 1(Suppl 1):35-8. [PMC free article: PMC3583176] [PubMed: 23503953]

2.Esteves SC, Miyaoka R, Agarwal A. An update on the clinical assessment of the infertile male. [corrected]. Clinics (Sao Paulo). 2011;66(4):691-700. [PMC free article: PMC3093801] [PubMed: 21655766]

3.Esteves SC, Agarwai A. The azoospermic male: current knowledge and future perspectives. Clinics (Sao Paulo). 2013;68 Suppl 1(Suppl 1):1-4. [PMC free article: PMC3583158] [PubMed: 23503949]

4.Jarvi K, Lo K, Grober E, Mak V, Fischer A, Grantmyre J, Zini A, Chan P, Patry G, Chow V, Domes T. The workup and management of azoospermic males. Can Urol Assoc J. 2015 Jul-Aug;9(7-8):229-35. [PMC free article: PMC4537331] [PubMed: 26316904]

5.Jarow JP, Espeland MA, Lipshultz LI. Evaluation of the azoospermic patient. J Urol. 1989 Jul;142(1):62-5. [PubMed: 2499695]

6.Jarvi K, Lo K, Fischer A, Grantmyre J, Zini A, Chow V, Mak V. CUA Guideline: The workup of azoospermic males. Can Urol Assoc J. 2010 Jun;4(3):163-7. [PMC free article: PMC2874589] [PubMed: 20514278]

7.Wosnitzer M, Goldstein M, Hardy MP. Review of Azoospermia. Spermatogenesis. 2014;4:e28218. [PMC free article: PMC4124057] [PubMed: 25105055]

8.Moon MH, Kim SH, Cho JY, Seo JT, Chun YK. Scrotal US for evaluation of infertile men with azoospermia. Radiology. 2006 Apr;239(1):168-73. [PubMed: 16467212]

9.Esteves SC, Miyaoka R, Agarwal A. Sperm retrieval techniques for assisted reproduction. Int Braz J Urol. 2011 Sep-Oct;37(5):570-83. [PubMed: 22099268]

10.Belva F, De Schrijver F, Tournaye H, Liebaers I, Devroey P, Haentjens P, Bonduelle M. Neonatal outcome of 724 children born after ICSI using non-ejaculated sperm. Hum Reprod. 2011 Jul;26(7):1752-8. [PubMed: 21511713]

11.Esteves SC, Prudencio C, Seol B, Verza S, Knoedler C, Agarwal A. Comparison of sperm retrieval and reproductive outcome in azoospermic men with testicular failure and obstructive azoospermia treated for infertility. Asian J Androl. 2014 Jul-Aug;16(4):602-6. [PMC free article: PMC4104090] [PubMed: 24759580]

12.Yassa NA, Keesara S. Role of transrectal ultrasonography in evaluating the cause of azoospermia. Can Assoc Radiol J. 2001 Aug;52(4):266-8. [PubMed: 11512301]

13.Smajlovic F. Role of transrectal ultrasonography in evaluting azoospermia causes. Med Arh. 2007;61(1):37-9. [PubMed: 17582974]

14.Esteves SC. Clinical management of infertile men with nonobstructive azoospermia. Asian J Androl. 2015 May-Jun;17(3):459-70. [PMC free article: PMC4430952] [PubMed: 25677138]

15.Peña VN, Kohn TP, Herati AS. Genetic mutations contributing to non-obstructive azoospermia. Best Pract Res Clin Endocrinol Metab. 2020 Dec;34(6):101479. [PubMed: 33390350]

16.Saliev T, Fakhradiyev I, Tanabayeva S, Assanova Y, Toishybek D, Kazybayeva A, Tanabayev B, Sikhymbaev M, Alimbayeva A, Toishibekov Y. Radio-Protective effect of aminocaproic acid in human spermatozoa. Int J Radiat Biol. 2022;98(9):1462-1472. [PubMed: 35021023]

17.Saliev T, Baiskhanova D, Beznosko D, Begimbetova D, Umbayev B, Nurgozhin T, Fakhradiyev I, Tanabayev B, Pavalkis D. A New Insight on the Radioprotective Potential of Epsilon-Aminocaproic Acid. Medicina (Kaunas). 2020 Nov 30;56(12) [PMC free article: PMC7760922] [PubMed: 33266046]

18.Cocuzza M, Alvarenga C, Pagani R. The epidemiology and etiology of azoospermia. Clinics (Sao Paulo). 2013;68 Suppl 1(Suppl 1):15-26. [PMC free article: PMC3583160] [PubMed: 23503951]

19.Chandra A, Copen CE, Stephen EH. Infertility service use in the United States: data from the National Survey of Family Growth, 1982-2010. Natl Health Stat Report. 2014 Jan 22;(73):1-21. [PubMed: 24467919]

20.Eisenberg ML, Betts P, Herder D, Lamb DJ, Lipshultz LI. Increased risk of cancer among azoospermic men. Fertil Steril. 2013 Sep;100(3):681-5. [PMC free article: PMC3759541] [PubMed: 23790640]

21.Petersen PM, Skakkebaek NE, Vistisen K, Rørth M, Giwercman A. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol. 1999 Mar;17(3):941-7. [PubMed: 10071288]

22.Cates W, Farley TM, Rowe PJ. Worldwide patterns of infertility: is Africa different? Lancet. 1985 Sep 14;2(8455):596-8. [PubMed: 2863605]

23.Nudell DM, Conaghan J, Pedersen RA, Givens CR, Schriock ED, Turek PJ. The mini-micro-epididymal sperm aspiration for sperm retrieval: a study of urological outcomes. Hum Reprod. 1998 May;13(5):1260-5. [PubMed: 9647557]

24.Sussman EM, Chudnovsky A, Niederberger CS. Hormonal evaluation of the infertile male: has it evolved? Urol Clin North Am. 2008 May;35(2):147-55, vii. [PubMed: 18423236]

25.Burrows PJ, Schrepferman CG, Lipshultz LI. Comprehensive office evaluation in the new millennium. Urol Clin North Am. 2002 Nov;29(4):873-94. [PubMed: 12516759]

26.Visser AJ, Heyns CF. Testicular function after torsion of the spermatic cord. BJU Int. 2003 Aug;92(3):200-3. [PubMed: 12887467]

27.Paduch DA, Bolyakov A, Cohen P, Travis A. Reproduction in men with Klinefelter syndrome: the past, the present, and the future. Semin Reprod Med. 2009 Mar;27(2):137-48. [PubMed: 19247915]

28.Schiff JD, Palermo GD, Veeck LL, Goldstein M, Rosenwaks Z, Schlegel PN. Success of testicular sperm extraction [corrected] and intracytoplasmic sperm injection in men with Klinefelter syndrome. J Clin Endocrinol Metab. 2005 Nov;90(11):6263-7. [PubMed: 16131585]

29.Kohn TP, Louis MR, Pickett SM, Lindgren MC, Kohn JR, Pastuszak AW, Lipshultz LI. Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy. Fertil Steril. 2017 Feb;107(2):351-357.e1. [PMC free article: PMC5292276] [PubMed: 27855957]

30.McCallum T, Milunsky J, Munarriz R, Carson R, Sadeghi-Nejad H, Oates R. Unilateral renal agenesis associated with congenital bilateral absence of the vas deferens: phenotypic findings and genetic considerations. Hum Reprod. 2001 Feb;16(2):282-8. [PubMed: 11157821]

31.Matsuda T, Horii Y, Yoshida O. Unilateral obstruction of the vas deferens caused by childhood inguinal herniorrhaphy in male infertility patients. Fertil Steril. 1992 Sep;58(3):609-13. [PubMed: 1521659]

32.Pryor JP, Hendry WF. Ejaculatory duct obstruction in subfertile males: analysis of 87 patients. Fertil Steril. 1991 Oct;56(4):725-30. [PubMed: 1915949]

33.Goldwasser BZ, Weinerth JL, Carson CC. Ejaculatory duct obstruction: the case for aggressive diagnosis and treatment. J Urol. 1985 Nov;134(5):964-6. [PubMed: 4057387]

34.Smith JF, Walsh TJ, Turek PJ. Ejaculatory duct obstruction. Urol Clin North Am. 2008 May;35(2):221-7, viii. [PubMed: 18423242]

35.Steckel J, Dicker AP, Goldstein M. Relationship between varicocele size and response to varicocelectomy. J Urol. 1993 Apr;149(4):769-71. [PubMed: 8455240]

36.Jarow JP, Ogle SR, Eskew LA. Seminal improvement following repair of ultrasound detected subclinical varicoceles. J Urol. 1996 Apr;155(4):1287-90. [PubMed: 8632555]

37.Lipshultz LI, Corriere JN. Progressive testicular atrophy in the varicocele patient. J Urol. 1977 Feb;117(2):175-6. [PubMed: 833961]

38.Minhas S, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, Cocci A, Corona G, Dimitropoulos K, Gül M, Hatzichristodoulou G, Jones TH, Kadioglu A, Martínez Salamanca JI, Milenkovic U, Modgil V, Russo GI, Serefoglu EC, Tharakan T, Verze P, Salonia A., EAU Working Group on Male Sexual and Reproductive Health. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2021 Update on Male Infertility. Eur Urol. 2021 Nov;80(5):603-620. [PubMed: 34511305]

39.Ishikawa T, Fujioka H, Fujisawa M. Clinical and hormonal findings in testicular maturation arrest. BJU Int. 2004 Dec;94(9):1314-6. [PubMed: 15610112]

40.Kim HH, Schlegel PN. Endocrine manipulation in male infertility. Urol Clin North Am. 2008 May;35(2):303-18, x. [PubMed: 18423250]

41.Schoor RA, Elhanbly S, Niederberger CS, Ross LS. The role of testicular biopsy in the modern management of male infertility. J Urol. 2002 Jan;167(1):197-200. [PubMed: 11743304]

42.Büchter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol. 1998 Sep;139(3):298-303. [PubMed: 9758439]

43.Al Hashimi M, Farahat Y, Kandil H, Al Khalidi I. Androgenic-anabolic steroid abuse trend and management: A prospective, cross-sectional, questionnaire-based survey. Health Sci Rep. 2023 Jan;6(1):e1032. [PMC free article: PMC9827233] [PubMed: 36628108]

44.Ko EY, Siddiqi K, Brannigan RE, Sabanegh ES. Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association. J Urol. 2012 Mar;187(3):973-8. [PubMed: 22264467]

45.Kolettis PN, Purcell ML, Parker W, Poston T, Nangia AK. Medical testosterone: an iatrogenic cause of male infertility and a growing problem. Urology. 2015 May;85(5):1068-1073. [PubMed: 25819620]

46.McBride JA, Coward RM. Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian J Androl. 2016 May-Jun;18(3):373-80. [PMC free article: PMC4854084] [PubMed: 26908067]

47.Sihag P, Tandon A, Pal R, Bhatt S, Sinha A, Sumbul M. Sonography in male infertility: a useful yet underutilized diagnostic tool. J Ultrasound. 2022 Sep;25(3):675-685. [PMC free article: PMC9402860] [PubMed: 35038143]

48.Morel F, Douet-Guilbert N, Le Bris MJ, Amice V, Le Martelot MT, Roche S, Valéri A, Derrien V, Amice J, De Braekeleer M. Chromosomal abnormalities in couples undergoing intracytoplasmic sperm injection. A study of 370 couples and review of the literature. Int J Androl. 2004 Jun;27(3):178-82. [PubMed: 15139974]

49.Groth KA, Skakkebæk A, Høst C, Gravholt CH, Bojesen A. Clinical review: Klinefelter syndrome–a clinical update. J Clin Endocrinol Metab. 2013 Jan;98(1):20-30. [PubMed: 23118429]

50.Corona G, Pizzocaro A, Lanfranco F, Garolla A, Pelliccione F, Vignozzi L, Ferlin A, Foresta C, Jannini EA, Maggi M, Lenzi A, Pasquali D, Francavilla S., Klinefelter ItaliaN Group (KING). Sperm recovery and ICSI outcomes in Klinefelter syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2017 May 01;23(3):265-275. [PubMed: 28379559]

51.Yang Q, Huang YP, Wang HX, Hu K, Wang YX, Huang YR, Chen B. Follicle-stimulating hormone as a predictor for sperm retrieval rate in patients with nonobstructive azoospermia: a systematic review and meta-analysis. Asian J Androl. 2015 Mar-Apr;17(2):281-4. [PMC free article: PMC4650470] [PubMed: 25337843]

52.Rohayem J, Fricke R, Czeloth K, Mallidis C, Wistuba J, Krallmann C, Zitzmann M, Kliesch S. Age and markers of Leydig cell function, but not of Sertoli cell function predict the success of sperm retrieval in adolescents and adults with Klinefelter’s syndrome. Andrology. 2015 Sep;3(5):868-75. [PubMed: 26235799]

53.Okada H, Goda K, Yamamoto Y, Sofikitis N, Miyagawa I, Mio Y, Koshida M, Horie S. Age as a limiting factor for successful sperm retrieval in patients with nonmosaic Klinefelter’s syndrome. Fertil Steril. 2005 Dec;84(6):1662-4. [PubMed: 16359961]

54.Franik S, Hoeijmakers Y, D’Hauwers K, Braat DD, Nelen WL, Smeets D, Claahsen-van der Grinten HL, Ramos L, Fleischer K. Klinefelter syndrome and fertility: sperm preservation should not be offered to children with Klinefelter syndrome. Hum Reprod. 2016 Sep;31(9):1952-9. [PubMed: 27412247]

55.Kanakis GA, Nieschlag E. Klinefelter syndrome: more than hypogonadism. Metabolism. 2018 Sep;86:135-144. [PubMed: 29382506]

56.Johnson MD. Genetic risks of intracytoplasmic sperm injection in the treatment of male infertility: recommendations for genetic counseling and screening. Fertil Steril. 1998 Sep;70(3):397-411. [PubMed: 9757865]

57.Clementini E, Palka C, Iezzi I, Stuppia L, Guanciali-Franchi P, Tiboni GM. Prevalence of chromosomal abnormalities in 2078 infertile couples referred for assisted reproductive techniques. Hum Reprod. 2005 Feb;20(2):437-42. [PubMed: 15567875]

58.Vincent MC, Daudin M, De MP, Massat G, Mieusset R, Pontonnier F, Calvas P, Bujan L, Bourrouillout G. Cytogenetic investigations of infertile men with low sperm counts: a 25-year experience. J Androl. 2002 Jan-Feb;23(1):18-22; discussion 44-5. [PubMed: 11780918]

59.Mak V, Jarvi KA. The genetics of male infertility. J Urol. 1996 Oct;156(4):1245-56; discussion 1256-7. [PubMed: 8808848]

60.Stahl PJ, Masson P, Mielnik A, Marean MB, Schlegel PN, Paduch DA. A decade of experience emphasizes that testing for Y microdeletions is essential in American men with azoospermia and severe oligozoospermia. Fertil Steril. 2010 Oct;94(5):1753-6. [PubMed: 19896650]

61.Yuen W, Golin AP, Flannigan R, Schlegel PN. Histology and sperm retrieval among men with Y chromosome microdeletions. Transl Androl Urol. 2021 Mar;10(3):1442-1456. [PMC free article: PMC8039602] [PubMed: 33850779]

62.Sudhakar DVS, Shah R, Gajbhiye RK. Genetics of Male Infertility – Present and Future: A Narrative Review. J Hum Reprod Sci. 2021 Jul-Sep;14(3):217-227. [PMC free article: PMC8527069] [PubMed: 34759610]

63.Schlegel PN. Testicular sperm extraction: microdissection improves sperm yield with minimal tissue excision. Hum Reprod. 1999 Jan;14(1):131-5. [PubMed: 10374109]

64.Kavoussi PK, Hudson K, Machen GL, Barsky M, Lebovic DI, Kavoussi SK. FSH levels and testicular volumes are associated with the severity of testicular histopathology in men with non-obstructive azoospermia. J Assist Reprod Genet. 2021 Nov;38(11):3015-3018. [PMC free article: PMC8608933] [PubMed: 34532836]

65.Marmar JL, Benoff S. Varicoceles. J Urol. 2006 Mar;175(3 Pt 1):818-9. [PubMed: 16469559]

66.Cocuzza M, Cocuzza MA, Bragais FM, Agarwal A. The role of varicocele repair in the new era of assisted reproductive technology. Clinics (Sao Paulo). 2008 Jun;63(3):395-404. [PMC free article: PMC2664231] [PubMed: 18568252]

67.Cocuzza M, Athayde KS, Agarwal A, Pagani R, Sikka SC, Lucon AM, Srougi M, Hallak J. Impact of clinical varicocele and testis size on seminal reactive oxygen species levels in a fertile population: a prospective controlled study. Fertil Steril. 2008 Oct;90(4):1103-8. [PubMed: 18022168]

68.Schlegel PN, Kaufmann J. Role of varicocelectomy in men with nonobstructive azoospermia. Fertil Steril. 2004 Jun;81(6):1585-8. [PubMed: 15193481]

69.Mathers MJ, Sperling H, Rübben H, Roth S. The undescended testis: diagnosis, treatment and long-term consequences. Dtsch Arztebl Int. 2009 Aug;106(33):527-32. [PMC free article: PMC2737432] [PubMed: 19738919]

70.Grasso M, Buonaguidi A, Lania C, Bergamaschi F, Castelli M, Rigatti P. Postpubertal cryptorchidism: review and evaluation of the fertility. Eur Urol. 1991;20(2):126-8. [PubMed: 1684324]

71.Raman JD, Schlegel PN. Testicular sperm extraction with intracytoplasmic sperm injection is successful for the treatment of nonobstructive azoospermia associated with cryptorchidism. J Urol. 2003 Oct;170(4 Pt 1):1287-90. [PubMed: 14501743]

72.Williamson RC. Torsion of the testis and allied conditions. Br J Surg. 1976 Jun;63(6):465-76. [PubMed: 6106]

73.Watkin NA, Reiger NA, Moisey CU. Is the conservative management of the acute scrotum justified on clinical grounds? Br J Urol. 1996 Oct;78(4):623-7. [PubMed: 8944521]

74.Schlegel PN, Palermo GD, Alikani M, Adler A, Reing AM, Cohen J, Rosenwaks Z. Micropuncture retrieval of epididymal sperm with in vitro fertilization: importance of in vitro micromanipulation techniques. Urology. 1995 Aug;46(2):238-41. [PubMed: 7624993]

75.Janzen N, Goldstein M, Schlegel PN, Palermo GD, Rosenwaks Z, Hariprashad J. Use of electively cryopreserved microsurgically aspirated epididymal sperm with IVF and intracytoplasmic sperm injection for obstructive azoospermia. Fertil Steril. 2000 Oct;74(4):696-701. [PubMed: 11020509]

76.Schlegel PN. Causes of azoospermia and their management. Reprod Fertil Dev. 2004;16(5):561-72. [PubMed: 15367371]

77.Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male Reproduction and Urology. Electronic address: [email protected]. The management of obstructive azoospermia: a committee opinion. Fertil Steril. 2019 May;111(5):873-880. [PubMed: 31029241]

78.Etafy M, Gudeloglu A, Brahmbhatt JV, Parekattil SJ. Review of the role of robotic surgery in male infertility. Arab J Urol. 2018 Mar;16(1):148-156. [PMC free article: PMC5922003] [PubMed: 29713546]

79.Avellino GJ, Lipshultz LI, Sigman M, Hwang K. Transurethral resection of the ejaculatory ducts: etiology of obstruction and surgical treatment options. Fertil Steril. 2019 Mar;111(3):427-443. [PubMed: 30827517]

80.Jiang HT, Yuan Q, Liu Y, Liu ZQ, Zhou ZY, Xiao KF, Yang JG. Multiple advanced surgical techniques to treat acquired seminal duct obstruction. Asian J Androl. 2014 Nov-Dec;16(6):912-6. [PMC free article: PMC4236339] [PubMed: 25337841]

81.Ghalayini IF, Alazab R, Halalsheh O, Al-Mohtaseb AH, Al-Ghazo MA. Repeated microdissection testicular sperm extraction in patients with non-obstructive azoospermia: Outcome and predictive factors. Arab J Urol. 2022;20(3):137-143. [PMC free article: PMC9354641] [PubMed: 35935909]

82.Ly LP, Liu PY, Handelsman DJ. Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens. Hum Reprod. 2005 Jun;20(6):1733-40. [PubMed: 15860500]

83.Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C., Hormonal Male Contraception Summit Group. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006 Apr 29;367(9520):1412-20. [PubMed: 16650651]

84.Rastrelli G, Corona G, Mannucci E, Maggi M. Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. Andrology. 2014 Nov;2(6):794-808. [PubMed: 25271205]

85.Selman H, De Santo M, Sterzik K, Cipollone G, Aragona C, El-Danasouri I. Rescue of spermatogenesis arrest in azoospermic men after long-term gonadotropin treatment. Fertil Steril. 2006 Aug;86(2):466-8. [PubMed: 16753161]

86.Shiraishi K, Ohmi C, Shimabukuro T, Matsuyama H. Human chorionic gonadotrophin treatment prior to microdissection testicular sperm extraction in non-obstructive azoospermia. Hum Reprod. 2012 Feb;27(2):331-9. [PubMed: 22128297]

87.Hussein A, Ozgok Y, Ross L, Rao P, Niederberger C. Optimization of spermatogenesis-regulating hormones in patients with non-obstructive azoospermia and its impact on sperm retrieval: a multicentre study. BJU Int. 2013 Mar;111(3 Pt B):E110-4. [PubMed: 22958644]

88.Tharakan T, Salonia A, Corona G, Dhillo W, Minhas S, Jayasena C. The Role of Hormone Stimulation in Men With Nonobstructive Azoospermia Undergoing Surgical Sperm Retrieval. J Clin Endocrinol Metab. 2020 Dec 01;105(12) [PubMed: 32810280]

89.Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002 Sep;87(9):4128-36. [PubMed: 12213860]

90.Bhasin S. Approach to the infertile man. J Clin Endocrinol Metab. 2007 Jun;92(6):1995-2004. [PubMed: 17554051]

91.Resorlu B, Abdulmajed MI, Kara C, Unsal A, Aydos K. Is intracytoplasmic sperm injection essential for the treatment of hypogonadotrophic hypogonadism? A comparison between idiopathic and secondary hypogonadotrophic hypogonadism. Hum Fertil (Camb). 2009 Dec;12(4):204-8. [PubMed: 19824804]

92.Bobjer J, Naumovska M, Giwercman YL, Giwercman A. High prevalence of androgen deficiency and abnormal lipid profile in infertile men with non-obstructive azoospermia. Int J Androl. 2012 Oct;35(5):688-94. [PubMed: 22519695]

93.Patel DP, Brant WO, Myers JB, Zhang C, Presson AP, Johnstone EB, Dorais JA, Aston KI, Carrell DT, Hotaling JM. Sperm concentration is poorly associated with hypoandrogenism in infertile men. Urology. 2015 May;85(5):1062-1067. [PubMed: 25735445]

94.Kalsi J, Thum MY, Muneer A, Abdullah H, Minhas S. In the era of micro-dissection sperm retrieval (m-TESE) is an isolated testicular biopsy necessary in the management of men with non-obstructive azoospermia? BJU Int. 2012 Feb;109(3):418-24. [PubMed: 21883824]

95.Bang JK, Lim JJ, Choi J, Won HJ, Yoon TK, Hong JY, Park DS, Song SH. Reversible infertility associated with testosterone therapy for symptomatic hypogonadism in infertile couple. Yonsei Med J. 2013 May 01;54(3):702-6. [PMC free article: PMC3635615] [PubMed: 23549818]

96.Wheeler KM, Sharma D, Kavoussi PK, Smith RP, Costabile R. Clomiphene Citrate for the Treatment of Hypogonadism. Sex Med Rev. 2019 Apr;7(2):272-276. [PubMed: 30522888]

Disclosure: Medhavi Sharma declares no relevant financial relationships with ineligible companies.

Disclosure: Stephen Leslie declares no relevant financial relationships with ineligible companies.